Who are BioClin Therapeutics's investors?

BioClin Therapeutics's investors include HealthCap, Inkef, Sectoral Asset Management, Sofinnova Ventures, Ysios Capital.

How much funding has BioClin Therapeutics raised?

BioClin Therapeutics has disclosed $86M raised across 5 rounds.

Where is BioClin Therapeutics headquartered?

BioClin Therapeutics is headquartered in San Leandro, US.

BioClin Therapeutics

San Leandro, US · Founded 2010 · Delaware corporation · 5 known investors

Find your way into BioClin Therapeutics

689 people in our graph share verified history with the BioClin Therapeutics team — schools, employers, funds. One of them is your warm intro.

Alan Abbottunlockedknows Kenneth Schwartz · together at Stanford University (overlapped)

×2knows the team · via Johnson & Johnson

×8knows the team · via Stanford University

knows the team · via Amgen

Biotech

Founders & leadership

Steve Abella inChief Medical Officer2017–2020Steve Abella is a physician and oncology specialist with over 35 years of experience in clinical research and biopharmaceutical development, including senior roles at Amgen and Gilead Sciences. He serves as Chief Medical Officer at BioClin Therapeutics, where he develops clinical strategies for oncology programs and advises biotechnology companies on regulatory pathways and development planning.

Graeme CurrieinChief Operating Officer

Stephen W. Lau inPresident, Chief Executive Officer, and TreasurerStephen W. Lau is President, CEO, and Treasurer of BioClin Therapeutics, a company he founded; previously held C-level roles (COO, CBO, CFO) at large biotechs and startups including Amgen, Anthera, and Innovent Biologics, and worked in biotech investment banking at Canaccord. He has led clinical development programs across oncology, immunology, neuroscience, and genetic medicine, and has experience in fundraising, licensing, and M&A transactions in the biotech sector.

Kenneth Schwartz inChief Medical Officer2013–2016Kenneth Schwartz leads clinical development and regulatory affairs at BioClin Therapeutics. He has spent his career overseeing small molecule and biologic clinical trials across multiple phases, including IND and NDA submissions, with regulatory experience in growth disorders, rheumatology, oncology, gastroenterology, and metabolic diseases.

Eric Yuen inVice President, Clinical Development2014–2015Eric Yuen holds an M.D. from the University of Chicago and completed neurology residency and postdoctoral fellowships at UCSF. He spent seven years as a faculty member and clinical researcher at the University of Washington before accumulating over 20 years of clinical development experience in the pharmaceutical industry, including senior roles as Chief Medical Officer at multiple companies (Ultragenyx, RiboNova, Inozyme, and Spirovant Sciences) and Vice President positions at Johnson & Johnson and Merck, leading drug development across rare genetic, neurological, psychiatric, pain, and oncology disorders.

Marten Steen in 𝕏Named on SEC filingManaging Partner at HealthCap

Christian RichardNamed on SEC filing

Joel Jean-MairetNamed on SEC filing

Fouad AzzamNamed on SEC filing

Joseph L. TurnerNamed on SEC filing

David KabakoffNamed on SEC filing

Board

Jack NielsenBoard director

Investors · 5

HealthCapreportedStockholm

InkefreportedAmsterdam

Sectoral Asset ManagementreportedMontreal

Sofinnova VenturesreportedMenlo Park · $100K – $15M

Ysios CapitalreportedBarcelona · $5.4M – $21.6M

Reported raises · per SEC filings

Form D private placements

$86M disclosed across 5 rounds · 2012–2019

▶$10MraisedJul 2019 · 10 investors · Biotechnology

Rule 506(b)